SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
GALT

Galectin Therapeutics Inc (NASDAQ:GALT)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$2.81-$0.17 (-5.70%)
 
Market cap
$185M
Insider Score
Health Score
Analyst consensus
Listed since
Sep 4, 2002
Market Cap$185.06M-51.0%
Revenue (ttm)$0
Net Income-$23.19M+37.8%
EPS-$0.34+42.9%
Shares Out65.86M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume220,444
Open$2.99
Previous Close$2.98
Day's Range$2.78 - $2.99
52-Week Range$2.03 - $7.13
Beta0.38
AnalystsBuy
Price Target$11.00(+291.46%)
Earnings DateMar 30, 2027

About GALT

Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stages for the management of cardiac and vascular fibrosis. The company is also actively exploring additional uses for belapectin in conditions like psoriasis, lung fibrosis, and kidney fibrosis. Furthermore, through Galectin Sciences, LLC – a joint venture established with SBH Sciences, Inc. – the firm is involved in researching and developing small organic molecules designed to block galectin-3, intended for oral administration. Established in 2000, the company was initially known as Pro-Pharmaceuticals, Inc. before officially changing its name to Galectin Therapeutics, Inc. in May 2011. Its corporate headquarters are located in Norcross, Georgia.

Address
4960 Peachtree Industrial Boulevard, Norcross, GA, 30071, US
Market Cap
185 million
Employees
9
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$1.25M
Bought
$219.38K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Distressed
From GALT’s reported statements · Q3 2026 (trailing 12 months) · 3 of 5 pillars

Next catalysts

1 Day
-5.70%
5 Days
-11.08%
1 Month
-18.08%
6 Months
+27.15%
1 Year
-51.05%

$GALT stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in GALT holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by GALT's directors and management

Net Shares Purchased by Insiders−200k−100k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

GALT Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New GALT patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to GALT from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in GALT

VTIVanguard Morningstar Total Stock Market ETF$3.98M
IWMiShares Russell 2000 ETF$3.53M
VXFVanguard Extended Market ETF$1.72M
IWOiShares Russell 2000 Growth ETF$935.23K
VTWOVanguard Russell 2000 ETF$934.11K
IWNiShares Russell 2000 Value ETF$464.14K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from GALT’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
8.35
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
72

News check: Rating upgrade to Buy, positive clinical data presentation, and routine financial updates support moderately bullish sentiment.

Recent Insider Activity

Buys
2
Sells
16
Buy Value
$219.38K
Distinct Buyers
2

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

MEDXHorizon Kinetics Medical ETF0.75%

Weight is the stock’s share of each fund’s holdings.